RNA Interference (RNAi): Market Research Report

March 2012 | 792 pages | ID: R624E3CC117EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 135 companies including many key and niche players such as Alnylam Pharmaceuticals, Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals, Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon, Inc., Dicerna Pharmaceuticals, Inc., Exiqon A/S, Genesis Research & Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina Biotech, Inc., OPKO Health, Inc., Polyplus-transfection SA, Quark Pharmaceuticals, Inc., Galena Biopharma, Sigma-Aldrich Co., Silence Therapeutics, and Tekmira Pharmaceuticals Corp.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Product Segments
Drug Discovery and Target Validation
Reagents
SiRNA Synthesis

II. EXECUTIVE SUMMARY

1.INDUSTRY OUTLOOK

RNA Interference: A Historic Perspective
RNAi Time Line

2.INDUSTRY OVERVIEW

Leading Regional Markets
High-throughput Screening: A Promising Application for RNA Interference
Growth Drivers

3.MARKET OUTLOOK

RNA Interference: A Potential Oligonucleotide Technology
A Review of Select Classes of Oligonucleotides Competing with siRNA
Oligonucleotide Market Sustains Recession
Select RNAi-based Therapeutics in the Pipeline
RNAi: A Leading Research Tool in Gene-Silencing
RNAi-based Drugs to Emerge as a New Class of Therapeutics
RNAi-based Therapeutics to Drive the Growth of RNAi Market
Statistics on Select Diseases
Cancer

Table 1. Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)

Table 2. Global Cancer Incidence by Country: 2009 (includes corresponding Graph/Chart)

Table 3. Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)

Table 4. Global Cancer Related Deaths in Male Population by Site: 2007 (includes corresponding Graph/Chart)

Table 5. Global Cancer Related Deaths in Female Population by Site: 2007(includes corresponding Graph/Chart)

Cardiovascular Diseases

Table 6. Global Coronary Heart Disease Prevalence by Region (includes corresponding Graph/Chart)

Table 7. Deaths Due to Major Cardiovascular Diseases in the US: Percentage Share Breakdown by Disease Type (includes corresponding Graph/Chart)

Huntington’s Disease (HD)
Diabetic Retinopathy

Table 8. Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart)

Table 9. Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)

Table 10. Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)

RNAi in Drug Therapeutics
RNAi: Select Targeted Clinical Areas
Age Related Macular Degeneration: A Key Clinical Area of Focus
Select Promising RNAi Drugs in Pipeline: A Review

ALN-VSP

Atu027

CALAA-01

CEQ501

RNAi Therapeutics: Challenges in a Nutshell
Drug Delivery: A Key Challenge Facing RNAi-based Therapeutics
Select Methods of Systemic Drug Delivery under Development
Select RNAi Drug Delivery Technologies under Development
Other Challenges Facing RNAi-based Therapeutics
A Snapshot of Select RNAi Delivery Platforms Under Development
Lipid Nanoparticle (LNP) siRNA Delivery Technology Platform (Tekmira)
RONDEL (Calando Pharmaceuticals)
Lipid and Polymer Based Delivery Platforms (Silence Therapeutics)
AtuPlex/AtuFect Delivery Platform
PolyTran™ Delivery Platform
RNAi Nanoplex Delivery Technology (Intradigm Corporation)
DiLA2 Platform (Marina Biotech)

4.PRODUCT OVERVIEW

History of RNA Interference
Co-Suppression and Quelling
VIGS (Virus Induced Gene Suppression)
RNA Interference or Post Transcriptional Silencing
The RNAi Pathway
siRNA and miRNA
RISC Complex
Transfer and Heritance
The Difference
Other Short RNAs mediating RNA Interference
Small Hairpin RNA (shRNA)
Repeat associated small interfering RNA (rasiRNA)
Comparison of Various Types of RNAs in RNA Interference

5.APPLICATIONS OF RNA INTERFERENCE

Significance of RNA Interference
Role of RNAi in Gene Silencing
RNA Interference Affects Protein Synthesis at the Level of Translation
Role of mRNA in Gene Expression
RNAi: Application Areas
RNAi in Drug Discovery and Target Validation
RNAi in Functional Genomics
Why RNAi over Other Techniques?
Use of RNAi in the Study of Functional Genomics in Humans
Model Organisms and Off-target Effects
Select Target Validation Systems
RNAiMonitor™ (Clontech Laboratories, Inc)
GenoExplorer™ microRNA System (GenoSensor Corp)
RNAi Reagents
Select RNAi Reagents and Transfection Kits
Lipofectamine™ RNAiMAX Transfection Reagent (Life Technologies/Invitrogen)
siGENOME® siRNA Reagents (Dharmacon RNA Technologies)
ON-TARGETplus™ SMARTpool Reagents (Dharmacon RNA Technologies)
Vector-based RNAi Reagents (Thermo Scientific)
siRNA transfection kits (Bio-Rad Lab)
Fluorescent Reagents (OZ Biosciences)
ICAFectin™ 442 siRNA Transfection Reagent (Tekmira)
TransIT®-mRNA Transfection Kit (Mirus Bio llc)
siRNA Synthesis
siRNA: A Popular Tool for the Detection and Induction of Gene Silencing
Methods of siRNA Synthesis
Select Synthetic siRNAs
Synthetic siRNAs (Eurogentec SA)
Ambion® In Vivo Pre-designed siRNAs (Life Technologies)
Silencer® Pre-Designed & Validated siRNAs (Life Technologies)
HuSH-29: pre-designed shRNA (OriGene Technologies, Inc.)
A Review of other Application Areas of RNAi
RNAi in Agriculture and Plant Biotechnology
miRNA as Biomarkers and Therapeutic Targets – An Insight
miRNA: Clinical Areas under Focus

6.REGULATORY APPROVALS

Asuragen Obtains Notices of Allowance for Several miRNA Patent Applications
Genable Technologies Obtains Orphan Designation by EMA
Benitec Obtains RNA Interference Patent from EPO
Silence Therapeutics Bags New Patent Rights
Benitec Receives RNAi Related Patent Grant from USPTO
Marina Obtains Notices of Allowance for siRNA Patent Applications
USPTO Grants a RNAi Related Patent to Benitec
Alnylam Receives Patent Rights for Woppmann Patent Series
Kylin Bags Patent Rights for pRNAi Technology
Allele Biotechnology Obtains Patent Approval for DNA-Encoded RNAi
Silence Therapeutics Obtains Notices of Allowance for RNAi Patent Applications
RXi Obtains Notices of Allowance for siRNA Patent Applications
Intradigm Obtains Patent for siRNA Sequence
Intradigm Receives Key RNAi Patent Allowance

7.TECHNOLOGICAL INNOVATIONS

Exiqon Launches miRCURY LNA™ miRNA Family Inhibitors
Cellecta Introduces New Open Source Genome-Wide RNAi Screening Platform
Tekmira, Alnylam, and UBC Co-Develop New Lipid Component
ID Tech Introduces Improved miRCat™ Small RNA Cloning System
Integrated DNA Technologies Launches Transductin™
Abnova Unveils New Gene Silencing Tool
Polyplus-transfection Introduces jetPRIME™ Transfection Reagent
Sigma-Aldrich Launches Gene-Specific MISSION esiRNA
CombiMatrix to Introduce miRNA Cancer-Screening Test in the US
GeneCopoeia Unveils microRNA Tools and Reagents for Functional Analysis
Invitrogen Introduces Invivofectamine™ Delivery Reagent

8.RECENT INDUSTRY ACTIVITY

RXi Pharmaceuticals Corp. is Now Galena Biopharma
Cenix to Establish New Subsidiary
Arrowhead Acquires Stake in US Subsidiary, Calando
RXi and Generex Obtain Positive Research Data for Exploring RNAi Technology
Rosetta Obtains Permit for miRNA-based Diagnostics in NY
Alnylam Pharmaceuticals Introduces Alnylam 5x15 Product Strategy
Cenix BioScience Receives R&D Grant from Saxony
Kyowa and Dicerna Expand Research Collaboration
MDRNA Acquires BNA Intellectual Property from Valeant
Sirnaomics Partners with a Chinese Company for RNAi Therapeutics Development
Kylin Obtains IRS Grant for Advancing Research on pRNAi Nanoparticle
Tekmira Obtains New License for Alnylam’s InterfeRx™
RXi to Collaborate with EyeGate
Sigma Life Partners with SwitchGear Genomics for miRNA Validation System
Marina Biotech Acquires Novosom’s SMARTICLES® Intellectual Property Estate
Quark to Collaborate with Nitto Denko for Co-Developing siRNA-based Anti-fibrotic Drug
AstraZeneca and Silence Therapeutics Extend R&D Alliance
Silence Therapeutics and AstraZeneca Extend siRNA Delivery Partnership
MDRNA to Take Over Cequent
Traversa and sanofi-aventis Ink Research Agreement
Pfizer to Develop HCV Compounds of Tacere Therapeutics
Intradigm and Silence Therapeutics Merge
Sirna Therapeutics and Allergan form Joint Drug Development Alliance
Benitec Collaborates with CCIA
RXi Pharmaceuticals Obtains Advirna’s RNAi Technology
RXi Obtains Exclusive Licensing Rights to Advirna’s Delivery Technologies
Dicerna Collaborates with Archemix
Alnylam Collaborates with GSK to Donate Several RNAi Technology Patents
AstraZeneca and Cenix Extend Research Agreement on RNA Interference
Allergan Stops Development of AGN-745 Treatment
Tekmira Inks Agreement with Roche
MDRNA Inks Licensing Agreement with Novartis
MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics
Mirna Therapeutics to Investigate Therapeutic Potential of miRNA
Cenix and Boehringer Ingelheim Ink Research Agreement
Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate Cancer
Cubist Partners with Alnylam Pharmaceuticals
Liquidia to License Certain Rights of PRINT technology to Abbott

9.STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER

Invitrogen Merges with Applied Biosystems
MDRNA Obtains Rights to RiboTask’s UNA Technology
Roche Takes Over Mirus
Thermo Fischer Snaps Up Open Biosystems
Protiva and Tekmira Complete the Merger of Business Operations
Takeda and Alnylam Enter into Strategic Alliance
SR Pharma Plc. is Now Silence Therapeutics Plc.

10.FOCUS ON SELECT GLOBAL PLAYERS

Alnylam Pharmaceuticals, Inc. (USA)
Benitec Limited (Australia)
Bioneer Corp. (Korea)
Calando Pharmaceuticals, Inc. (USA)
Cenix BioScience GmbH (Germany)
Devgen NV (Belgium)
Dharmacon, Inc. (USA)
Dicerna Pharmaceuticals, Inc. (USA)
Exiqon A/S (Denmark)
Genesis Research & Development Corporation Limited (New Zealand)
Halo-Bio RNAi Therapeutics, Inc. (USA)
Marina Biotech, Inc. (USA)
OPKO Health, Inc. (USA)
Polyplus-transfection SA (France)
Quark Pharmaceuticals, Inc. (USA)
Galena Biopharma (USA)
Sigma-Aldrich Co. (USA)
Silence Therapeutics (UK)
Tekmira Pharmaceuticals Corp. (Canada)

11.GLOBAL MARKET PERSPECTIVE

Table 11. World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 12. World Historic Review for RNA Interference by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 13. World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

Table 14. World Recent Past, Current & Future Analysis for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 15. World Historic Review for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 16. World 15-Year Perspective for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

Table 17. World Recent Past, Current & Future Analysis for RNA Interference Reagents by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 18. World Historic Review for RNA Interference Reagents by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 19. World 15-Year Perspective for RNA Interference Reagents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

Table 20. World Recent Past, Current & Future Analysis for siRNA Synthesis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)

Table 21. World Historic Review for siRNA Synthesis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 22. World 15-Year Perspective for siRNA Synthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Outlook
Technological Innovations
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 23. The US Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 24. The US Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 25. The US 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

2.CANADA

A. Market Analysis
Strategic Corporate Development
Focus on Select Major Player
B. Market Analytics

Table 26. Canadian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 27. Canadian Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 28. Canadian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

3.JAPAN

A. Market Analysis
Strategic Corporate Developments
B. Market Analytics

Table 29. Japanese Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 30. Japanese Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 31. Japanese 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4.EUROPE

Market Analytics

Table 32. European Recent Past, Current & Future Analysis for RNA Interference Market by Geographic Region – France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 33. European Historic Review for RNA Interference by Geographic Region – France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 34. European 15-Year Perspective for RNA Interference by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of European for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

Table 35. European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 36. European Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 37. European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4A.FRANCE

A. Market Analysis
Technological Innovation
Strategic Corporate Development
Focus on Select Major Player
B. Market Analytics

Table 38. French Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 39. French Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 40. French 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4B.GERMANY

A. Market Analysis
Strategic Corporate Developments
B. Market Analytics

Table 41. German Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)

Table 42. German Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 43. German 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4C.ITALY

Market Analytics

Table 44. Italian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 45. Italian Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 46. Italian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

4D.THE UNITED KINGDOM

A. Market Analysis
Technological Innovations
Focus on Select Major Player
B. Market Analytics

Table 47. The UK Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 48. The UK Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 49. The UK 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4E.REST OF EUROPE

A. Market Analysis
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 50. Rest of European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 51. Rest of European Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 52. Rest of European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

5.ASIA-PACIFIC

A. Market Analysis
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 53. Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently nalyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 54. Asia-Pacific Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 55. Asia-Pacific 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6.REST OF WORLD

Market Analytics

Table 56. Rest of World Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 57. Rest of World Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 58. Rest of World 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 135 (including Divisions/Subsidiaries - 139)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Africa
Middle East